Orient Europharma Co (ROCO:4120) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4120 Orient Europharma Co Ltd ROCO:4120
60 GF Score
Price NT$44.40
GF Value NT$44.98
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Orient Europharma Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Orient Europharma Co Valuation Rank Related Terms

ROCO:4120
60GF Score
Orient Europharma Co Ltd ROCO:4120
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued. The current stock price of NT$44.40 is trading 1.3% below its estimated GF Value™ of NT$44.98. GuruFocus considers Orient Europharma Co to be Fairly Valued.

Key valuation signals for ROCO:4120:

  • Valuation Rank:
  • GF Value™: NT$44.98 vs. price of NT$44.40 (1.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Europharma Co Business Description

Address 13th Floor, No. 128, Chengde Road, Section 6, Beitou District, Taipei, TWN, 112052
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
60GF Score

Get the complete analysis for ROCO:4120

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$44.40
Price
NT$44.98
GF Value